

Nanobodies as structural probes for the pathological aggregation of the Parkinson's disease associated protein α -synuclein

Tim Guilliams^a, Joke Wellens^b, Alexander K. Buell^a, Farah El-Turk^a, Elizabeth O'Day^c, Els Pardon^b, Jan Steyaert^b, Mark E Welland^d, John Christodoulou^e, Michele Vendruscolo^a, Christopher M Dobson^a, Erwin De Genn^a



PARKINSON'S UK
CHANGE ATTITUDES.
FIND A CURE.
JOIN US.

^aDepartment of Chemistry, University of Cambridge, Lensfield Road, Cambridge, CB2 1EW, UK.

^bStructural Biology Brussels, Department of Molecular and Cellular Interactions, Vlaams Instituut voor Biotechnologie, Vrije Universiteit Brussel, Pleinlaan 2, B-1050 Brussels, Belgium


^cDepartment of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA

^dNanoscience Centre, University of Cambridge, 11 JJ Thomson Avenue, West Cambridge, CB3 0FF, UK.


^eDepartment of Structural and Molecular Biology, University College London, London, WC1E 6BT, UK

α -synuclein and Parkinson's Disease


α -synuclein (α Syn) is a pre-synaptic protein of 140 residues and is believed to be a key player in the development of Parkinson's disease, a debilitating disorder caused by the loss of dopaminergic neurons of the Substantia nigra pars compacta of the brain. Although the amyloid form of α Syn is a pathological hallmark of Parkinson's disease, the fibrils themselves do not seem to be the most toxic species. As in other amyloid diseases, smaller oligomeric species that are formed early on the α -synuclein fibril-forming pathway, constitute the most toxic species that lead to cell death.



Epitope mapping by NMR spectroscopy




Probing fibril maturation by ITC



Nanobodies

Nanobodies are the antigen-binding domains of camel heavy chain antibodies. Nanobodies are small (10 times smaller than a full length antibody), they have a simple single domain antigen recognition motif and have up to pico-molar affinities. They are also extremely stable, very resistant to aggregation, can be very easily produced recombinant at high levels and are amenable to high-throughput protein engineering and have superior properties in bio-distribution, targeting and clearance



Crystal structure of α Syn:Nanobody

